Drug intelligence / Profile preview

EXO-PV-MAX

Development stage: Preclinical
Lead developer: Regenesys
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Topical

Overview

EXO-PV-MAX is a proprietary exosome-based biologic developed by Regenesys, specifically formulated as a triple-profile exosome matrix for intimate wellness applications. The product utilizes the regenerative potential of extracellular vesicles (exosomes) to support tissue repair and cellular rejuvenation in intimate tissues. As a triple-profile matrix, it is designed to deliver a synergistic blend of signaling molecules and growth factors to optimize cellular communication and promote regenerative outcomes. The therapy is part of Regenesys's broader pipeline of exosome-based products focused on regenerative medicine and wellness.

Brand names: EXO-PV-MAX
Other names: Triple-profile exosome matrix

Beyond the preview

Go deeper on EXO-PV-MAX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EXO-PV-MAX.

Explore the full profile